Fennec Pharmaceuticals Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Fennec Pharmaceuticals stock.
View analyst ratings for Fennec Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Fennec Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Fennec Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Fennec Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Fennec Pharmaceuticals.

Fennec Pharmaceuticals Inc (NASDAQ:FENC) issued its earnings results on Thursday, May, 13th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.03.
View Fennec Pharmaceuticals' earnings history.

Fennec Pharmaceuticals' stock was trading at $6.63 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, FENC shares have increased by 3.5% and is now trading at $6.86.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued 1 year price targets for Fennec Pharmaceuticals' stock. Their forecasts range from $11.00 to $17.00. On average, they anticipate Fennec Pharmaceuticals' share price to reach $13.50 in the next twelve months. This suggests a possible upside of 96.8% from the stock's current price.
View analysts' price targets for Fennec Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Fennec Pharmaceuticals include Curis (CRIS), MeiraGTx (MGTX), Cellectis (CLLS), TCR2 Therapeutics (TCRR), Osiris Therapeutics (OSIR), Adaptimmune Therapeutics (ADAP), Talaris Therapeutics (TALS), DBV Technologies (DBVT), Tarsus Pharmaceuticals (TARS), Precision BioSciences (DTIL), Orchard Therapeutics (ORTX), Poseida Therapeutics (PSTX), Compugen (CGEN), Ikena Oncology (IKNA) and Oyster Point Pharma (OYST).
View all of FENC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL).

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

Fennec Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.36%), Russell Investments Group Ltd. (0.76%), Northern Trust Corp (0.70%), Nuveen Asset Management LLC (0.39%), Morgan Stanley (0.16%) and UBS Group AG (0.16%).
View institutional ownership trends for Fennec Pharmaceuticals.

FENC stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Russell Investments Group Ltd., Morgan Stanley, Hartford Financial Management Inc., Nuveen Asset Management LLC, Goldman Sachs Group Inc., and AQR Capital Management LLC.
View insider buying and selling activity for Fennec Pharmaceuticals or view top insider-selling stocks.

FENC stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, GSA Capital Partners LLP, BlackRock Inc., JPMorgan Chase & Co., Virtu Financial LLC, and Barclays PLC.
View insider buying and selling activity for Fennec Pharmaceuticals or or view top insider-buying stocks.

Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FENC stock can currently be purchased for approximately $6.86.

Fennec Pharmaceuticals has a market capitalization of $178.38 million and generates $170,000.00 in revenue each year. The company earns $-18,110,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis.

The official website for Fennec Pharmaceuticals is www.fennecpharma.com.

Fennec Pharmaceuticals is headquartered at PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709.

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530.